WHAT ID IS DOING TO PRESERVE ANTIBIOTICS

The rapid increase of antibiotic resistance coupled with no new drugs to treat infections has created a perfect storm.

Every current antibiotic is a derivative of one discovered before 1982.

$1.8 billion Antimicrobial venture capital investment

Less than 5% of pharmaceutical venture capital goes to antimicrobials.

$38 billion Total pharmaceutical venture capital investment

Most major drug companies have reduced or quit antibiotic research and development.

Sales of antibiotics are small compared to other pharmaceuticals.

AVYCAZ (antibiotic) $75 million in sales 2 years post launch

MOST OTHER DRUGS $500 million to $1 billion in sales 2 years post launch

ID’S RESPONSE

As new infectious diseases threats continue to emerge, we need a robust, renewable antibiotic pipeline to meet current and future patient and public health needs.

- Remove barriers to developer entry by affecting the cost of R&D investments
- Provide incentives that offer financial return after a technology has been developed

Learn more: www.ValueofID.org